Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GB1211 (Selvigaltin) in Healthy Volunteers
NCT03809052Phase 1Completed
- Sponsor
- Galecto, Inc.
- Start
- Jan 2019
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of selvigaltin in Nonalcoholic steatohepatitis (NASH) and Liver Fibrosis (LF) (9 arms), sponsored by Galecto, Inc. Primary endpoint: Number of Participants With Adverse Events. Started Jan 2019; status: completed.
02
Drugs
selvigaltin
03
Conditions
Nonalcoholic steatohepatitis (NASH)Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT03809052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03809052.